Identification of an Estrogen-inducible Phosphatase (PP5) That Converts MCF-7 Human Breast Carcinoma Cells into an Estrogen-independent Phenotype when Expressed Constitutively*

The proliferation of many estrogen receptor (ER)-positive breast cancer cells depends on estradiol, and tumors arising from these cells are often responsive initially to treatment with selective ER modulators, which produce an antiestrogen effect. However, tumors that are refractory to the antiestrogenic effects of selective ER modulators often reemerge, and the prognosis for these patients is poor because of the lack of additional effective therapy. Accordingly, deciphering the cellular events associated with estrogen-dependent growth and the subsequent outgrowth of tumors with an estrogen-independent phenotype is of considerable interest. Here we show that the expression of PP5, an evolutionarily conserved Ser/Thr phosphatase that functions as an inhibitor of glucocorticoid- and p53-induced signaling cascades leading to growth suppression, is responsive to 17β-estradiol (E2) in ER-positive human breast carcinoma cells (MCF-7). Northern analysis revealed that E2-induced PP5 expression is blocked by treatment with tamoxifen, and a consensus ER recognition element was identified in the PP5 promoter. The PP5-ER recognition element associates with human ERs and confers E2-induced transcriptional activation to reporter plasmids. The specific inhibition of PP5 expression ablates E2-mediated proliferation in MCF-7 cells without having an apparent effect on E2-induced expression ofc-myc or cyclin D1. Thus, although critical for cell growth, PP5 likely acts either downstream or independently of c-Myc and Cyclin D1. To further characterize the role of PP5 in E2-regulated growth control, we constructed stable MCF-7 cell lines in which the expression of PP5 was placed under the control of tetracycline-regulated transactivator and operator plasmids. Studies with these cells revealed that the constitutive overexpression of PP5 affords E2-dependent MCF-7 cells with the ability to proliferate in E2-depleted media. Together, these studies indicate that E2-induced PP5 expression functions to enhance E2-initiated signaling cascades leading to cell division and that aberrant PP5 expression may contribute to the development of MCF-7 cells with an estrogen-independent phenotype.

[1]  A. Prescott,et al.  Nuclear localization of protein phosphatase 5 is dependent on the carboxy‐terminal region , 2001, FEBS letters.

[2]  J F Barrett,et al.  Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Varley,et al.  Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization , 1999, British Journal of Cancer.

[4]  K. Tomer,et al.  The Tetratricopeptide Repeat Domain and a C-terminal Region Control the Activity of Ser/Thr Protein Phosphatase 5* , 1999, The Journal of Biological Chemistry.

[5]  N. Dean,et al.  Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. , 1999, Biochemistry.

[6]  R. Buckle,et al.  Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. , 1998, Genes & development.

[7]  G. Sathya,et al.  Sequence Requirements for Estrogen Receptor Binding to Estrogen Response Elements* , 1998, The Journal of Biological Chemistry.

[8]  R. Sutherland,et al.  c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry , 1998, Molecular and Cellular Biology.

[9]  N. Dean,et al.  Serine/Threonine Protein Phosphatase Type 5 Acts Upstream of p53 to Regulate the Induction of p21WAF1/Cip1 and Mediate Growth Arrest* , 1998, The Journal of Biological Chemistry.

[10]  R. Sutherland,et al.  Estrogen regulation of cell cycle progression in breast cancer cells 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  Carolyn L. Smith,et al.  Cross-talk between peptide growth factor and estrogen receptor signaling pathways. , 1998, Biology of reproduction.

[12]  D. Donoghue,et al.  The Serine/Threonine Phosphatase PP5 Interacts with CDC16 and CDC27, Two Tetratricopeptide Repeat-containing Subunits of the Anaphase-promoting Complex* , 1997, The Journal of Biological Chemistry.

[13]  Shaying Zhao,et al.  Human Blue‐light Photoreceptor hCRY2 Specifically Interacts with Protein Serine/Threonine Phosphatase 5 and Modulates Its Activity , 1997, Photochemistry and photobiology.

[14]  R. Honkanen,et al.  Genomic organization of the human PP4 gene encoding a serine/threonine protein phosphatase (PP4) suggests a common ancestry with PP2A. , 1997, Genomics.

[15]  M. Ewen,et al.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 , 1997, Molecular and cellular biology.

[16]  R. Weinberg,et al.  Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution , 1997, Molecular and cellular biology.

[17]  R. Griffey,et al.  Identification and characterization of second-generation antisense oligonucleotides. , 1997, Antisense & nucleic acid drug development.

[18]  R. Sutherland,et al.  Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  R. Sutherland,et al.  Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2* , 1997, The Journal of Biological Chemistry.

[20]  R. Bernards,et al.  CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.

[21]  A. Silverstein,et al.  The Tetratricopeptide Repeat Domain of Protein Phosphatase 5 Mediates Binding to Glucocorticoid Receptor Heterocomplexes and Acts as a Dominant Negative Mutant* , 1996, The Journal of Biological Chemistry.

[22]  J. Bartek,et al.  Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint , 1996, Molecular and cellular biology.

[23]  H. Ponstingl,et al.  The novel human protein serine/threonine phosphatase 6 is a functional homologue of budding yeast Sit4p and fission yeast ppe1, which are involved in cell cycle regulation. , 1996, Journal of cell science.

[24]  L. Altucci,et al.  17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. , 1996, Oncogene.

[25]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[26]  G. Stamp,et al.  Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. , 1995, Genes & development.

[27]  S. Elledge,et al.  Cyclin D1 provides a link between development and oncogenesis in the retina and breast , 1995, Cell.

[28]  J. Foekens,et al.  Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.

[29]  J. Foekens,et al.  Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. , 1994, British Journal of Cancer.

[30]  Michael Chinkers Targeting of a distinctive protein-serine phosphatase to the protein kinase-like domain of the atrial natriuretic peptide receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Joost,et al.  Molecular cloning of a protein serine/threonine phosphatase containing a putative regulatory tetratricopeptide repeat domain. , 1994, The Journal of biological chemistry.

[32]  N. Dean,et al.  Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. , 1994, The Journal of biological chemistry.

[33]  K. Khanna,et al.  Cloning and characterization of a human protein phosphatase 1-encoding cDNA. , 1993, Gene.

[34]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. O’Malley,et al.  Dopaminergic and ligand-independent activation of steroid hormone receptors. , 1991, Science.

[36]  R. Stone UN claims victory in desert war. , 1991, Science.

[37]  P. Watson,et al.  Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. , 1991, Cancer research.

[38]  J. Farndon,et al.  EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.

[39]  M. Ptashne How eukaryotic transcriptional activators work , 1988, Nature.

[40]  J. Katzenellenbogen,et al.  Bis(4-hydroxyphenyl)[2-(phenoxysulfonyl)phenyl]methane: isolation and structure elucidation of a novel estrogen from commercial preparations of phenol red (phenolsulfonphthalein) , 1988, Journal of medicinal chemistry.

[41]  T. B. Miller,et al.  Human liver phosphatase 2A: cDNA and amino acid sequence of two catalytic subunit isotypes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[42]  F. Taggi SAFETY HELMET LAW IN ITALY , 1988, The Lancet.

[43]  R. Shiu,et al.  Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. , 1987, Cancer research.

[44]  J. Hofsteenge,et al.  Molecular cloning of cDNAs encoding two isoforms of the catalytic subunit of protein phosphatase 2A. , 1987, Biochemistry.

[45]  B. Leung,et al.  Mode of estrogen action on cell proliferation in CAMA‐1 cells: II. Sensitivity of G1 phase population , 1987, Journal of cellular biochemistry.

[46]  L. Murphy,et al.  Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. , 1987, Endocrinology.

[47]  T. Burrage,et al.  Hormonal induction of secretory granules in a pituitary tumor cell line. , 1986, Endocrinology.

[48]  R. Sutherland,et al.  Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. , 1983, European journal of cancer & clinical oncology.

[49]  P. Dannies,et al.  17β-ESTRADIOL HAS A BIPHASIC EFFECT ON GH CELL GROWTH1 , 1983 .

[50]  N. Spurr,et al.  Three genes for protein phosphatase 1 map to different human chromosomes: sequence, expression and gene localisation of protein serine/threonine phosphatase 1 beta (PPP1CB). , 1994, Biochimica et biophysica acta.

[51]  E. O. Johnson,et al.  Glucocorticoids inhibit estradiol-mediated uterine growth: possible role of the uterine estradiol receptor. , 1990, Biology of reproduction.

[52]  M. Lippman,et al.  The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. , 1976, Cancer research.